CN111757749A - 用于预防、改善或治疗肥胖和代谢性疾病的包含桃花和荷叶的组合提取物的组合物 - Google Patents
用于预防、改善或治疗肥胖和代谢性疾病的包含桃花和荷叶的组合提取物的组合物 Download PDFInfo
- Publication number
- CN111757749A CN111757749A CN201880084519.9A CN201880084519A CN111757749A CN 111757749 A CN111757749 A CN 111757749A CN 201880084519 A CN201880084519 A CN 201880084519A CN 111757749 A CN111757749 A CN 111757749A
- Authority
- CN
- China
- Prior art keywords
- lotus leaf
- peach blossom
- extract
- combined extract
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 119
- 235000006040 Prunus persica var persica Nutrition 0.000 title claims abstract description 88
- 240000002853 Nelumbo nucifera Species 0.000 title claims abstract description 85
- 235000006508 Nelumbo nucifera Nutrition 0.000 title claims abstract description 85
- 244000144730 Amygdalus persica Species 0.000 title claims abstract description 84
- 235000006510 Nelumbo pentapetala Nutrition 0.000 title claims abstract description 84
- 208000008589 Obesity Diseases 0.000 title claims abstract description 49
- 235000020824 obesity Nutrition 0.000 title claims abstract description 49
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 235000013305 food Nutrition 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 21
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 16
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 14
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 12
- 208000016097 disease of metabolism Diseases 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000004580 weight loss Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 229930014626 natural product Natural products 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 235000019197 fats Nutrition 0.000 description 17
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- 238000010172 mouse model Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000008103 glucose Substances 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 240000005809 Prunus persica Species 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- -1 olive oil Chemical compound 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
- 241000209445 Nelumbonaceae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000004789 Rosa xanthina Nutrition 0.000 description 2
- 241000220222 Rosaceae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 229960000182 blood factors Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000015071 dressings Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 235000011446 Amygdalus persica Nutrition 0.000 description 1
- 241000169680 Aphloia theiformis Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 235000015533 Prunus davidiana Nutrition 0.000 description 1
- 240000002381 Prunus davidiana Species 0.000 description 1
- 241001631271 Prunus fasciculata Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012182 cereal bars Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020931 dietary conditions Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GNHOJBNSNUXZQA-UHFFFAOYSA-J potassium aluminium sulfate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GNHOJBNSNUXZQA-UHFFFAOYSA-J 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及用于预防、改善或治疗肥胖或代谢性疾病的组合物,其包含作为活性成分的桃花和荷叶的组合提取物或其级分,及其用途和治疗方法。根据本发明的桃花和荷叶的组合提取物或其级分对肥胖或代谢性疾病具有优异的功效,且其源自天然产物并且没有副作用。因此,可以将组合提取物或其级分多方面地用作预防或治疗代谢性疾病的药物组合物、预防或改善肥胖或代谢性疾病的食品组合物或药物,或用于制造药物的使用或用于治疗方法。
Description
【技术领域】
本发明涉及用于预防或治疗肥胖或代谢性疾病的药物组合物和用于预防或改善肥胖或代谢性疾病的食品组合物,其各自包含桃花和荷叶的组合提取物或其级分作为活性成分。
【背景技术】
在现代社会中,以肉食为基础的饮食转换导致热量摄入过多且缺乏体育锻炼,因此代谢性疾病,包括肥胖、糖尿病、高脂血症、非酒精性脂肪肝和血脂异常等各种疾病的发病率迅速上升。
肥胖是指由于能量摄入超过能量消耗而在体内脂肪中积累过多能量的状态。当前使用的抗肥胖药的药理机制可大致分为1)抑制脂肪吸收,2)促进脂肪分解和热量产生,3)控制食欲和饱腹感,4)抑制蛋白质代谢和5)与食物摄入有关的情绪调节。代表性的抗肥胖药可能包括抑制脂肪吸收的XenicalTM和通过刺激交感神经系统抑制食欲的ReductilTM。然而,XenicalTM被报道具有如油性大便、腹痛、呕吐、瘙痒、肝损伤等副作用;而ReductilTM被报道具有如头痛、食欲不振、失眠、便秘等副作用以及严重的心血管副作用。
糖尿病是由胰岛素分泌不足或异常引起的疾病,其特征在于血糖水平升高(高血糖)和尿葡萄糖排泄的症状。当前使用的抗糖尿病药物包括PPAR-γ激活剂、GLP-1衍生物、DPP-IV抑制剂等,但是据报道,这些传统药物具有例如体重增加以及对肝脏、肾脏、肌肉、心脏等的毒性的副作用。
高脂血症被认为是这样一种疾病,其中血液中超标的脂肪成分积聚在血管壁上引起炎症,从而导致心血管疾病,例如心肌梗塞、中风、脑梗塞等。目前所用的抗高血脂药物包括具有HMG-CoA还原酶抑制活性的基于“他汀”的药物,但是据报道,长时间使用它们会具有例如对肝脏、肌肉等的毒性的副作用。
血脂异常是指血液中的总胆固醇、LDL胆固醇或甘油三酯水平升高而HDL胆固醇水平降低的病症,并且已知会增加心脏病发作、中风等心血管等疾病的风险。当前使用的抗血脂异常的药物包括可从拜耳公司获得的BAY13-9952(英普他派implitapide),其是抑制微粒体甘油三酸酯转移蛋白(MTP)活性的药物。但是,这些药物的问题在于细胞内的作用机理尚不清楚,并且可能引起副作用。
非酒精性脂肪性肝病,其是由脂肪性肝病中除酒精以外的其他因素引起的脂肪性肝病,是指在超过5%肝实质细胞中以甘油三酸酯形式的脂肪酸积累。非酒精性脂肪肝疾病在病理上分为简单脂肪变性和具有炎症的脂肪性肝炎。众所周知,如果长时间不治疗,非酒精性脂肪性肝炎可能会发展为严重的肝脏疾病,例如肝炎、肝纤维化、肝硬化等。非酒精性脂肪肝疾病难以开发其治疗方法,因为尚未明确其病因。特别地,由于靶器官--肝脏是发生各种排毒过程的器官,因此当使用具有增加的药理活性的药物时,存在肝细胞受损的风险,难以开发有效的药物。
用于肥胖或代谢性疾病的有效治疗剂的当前开发不足,并且据报道用于各种特定疾病的治疗剂具有各种副作用。因此,迫切需要开发对肥胖或代谢性疾病具有优异的治疗效果且无副作用的安全治疗剂。
【公开】
【技术问题】
本发明的主要目的是提供用于预防、改善或治疗肥胖或代谢性疾病的组合物,该组合物包含桃花和荷叶的组合提取物作为有效成分。
特别地,本发明的目的是提供一种用于预防或治疗肥胖或代谢性疾病的药物组合物,该药物组合物包括桃花和荷叶的组合提取物或其级分作为有效成分。
本发明的另一个目的是提供用于预防或改善肥胖或代谢性疾病的食品组合物,该食品组合物包括桃花和荷叶的组合提取物或其级分作为活性成分。
本发明的又一个目的是提供一种方法,其使用桃花和荷叶的组合提取物来治疗或预防肥胖或代谢性疾病。
此外,本发明的另一个目的是提供桃花和荷叶的组合提取物在制备用于肥胖或代谢性疾病的治疗剂中的用途。
【技术方案】
为了实现本发明的目的,本发明提供了药物组合物或食品组合物,其各自包含组合提取物或其级分作为活性成分。在下文中,将详细描述每种组合物。
预防或治疗肥胖或代谢性疾病的药物组合物
作为实现本发明目的的一个方面,本发明提供了一种用于预防或治疗肥胖或代谢性疾病的药物组合物,该药物组合物包括桃花和荷叶的组合提取物或其级分作为活性成分。
如本文所用,术语“桃花”是指属于蔷薇科(Rosaceae)家族的桃树或野生桃的花。桃花是直径约2.5厘米至3.5厘米的双性花,通常有浅红色、白色、深红色等品种。在4月中旬或5月初的开花期收集桃花,并且在阴凉处干燥后待用作草药。在本发明中,桃花可以是科学名称为桃(Prunus persica)或山桃(Prunus davidiana)的植物的花,但不限于此。
如本文所用,术语“桃花提取物”是指通过用水或有机溶剂提取桃花或花蕾而获得的提取物。
如本文所用,术语“荷叶”是指属于莲科(Nelumbonaceae)家族的荷叶。荷叶为半圆形或条纹扇形,但展开时为圆形,直径为20到50厘米。叶边缘平坦或为波浪形。叶的上表面为深绿色或黄绿色,下表面略有光泽,从叶柄的中心向各个方向延伸出21至22行伸出的叶脉。在本发明中,荷叶可以是科学名称为荷花(Nelumbo nucifera)的植物的叶,但不限于此。
如本文所用,术语“荷叶提取物”是指通过用水或有机溶剂提取荷叶而获得的提取物。
在本发明中,“桃花和荷叶的组合提取物”包括桃花提取物和荷叶提取物的混合物以及桃花和荷叶的混合物的提取物两者。
在本发明中,桃花提取物和荷叶提取物的混合物中的桃花提取物和荷叶提取物可以以10:1至1:10的重量比混合物,优选5:1至1:5,更优选3:1至1:3。
此外,在本发明中,桃花和荷叶的混合物中的桃花和荷叶可以以10:1至1:10的重量比混合,优选5:1至1:5,更优选3:1至1:3。
如本文所用,术语“提取物”包括液体提取物本身和可以使用该液体提取物制备的任何制剂的提取物,例如通过对天然物质进行提取处理而获得的液体提取物、液体提取物的稀释液或浓缩液、通过干燥液体提取物而获得的干燥产物,以及液体提取物的粗纯化产物或纯化产物,或其混合物等。
提取物的制备方法可以但不特别限于根据本领域通常使用的方法进行。提取方法的非限制性实例可包括热水提取法、超声提取法、过滤法、回流提取法、浸没提取法、高温高压蒸汽提取法等,且这些方法可以单独或以其两种或以上的组合进行。
在本发明中,提取天然物质中使用的提取溶剂的种类没有特别限制,可以使用本领域已知的任何溶剂。提取溶剂的非限制性实例可以包括水、醇、其混合物等。当使用醇作为溶剂时,可以优选使用C1-C4醇,并且可以更优选使用甲醇或乙醇。最优选地,水、30%至80%的甲醇(v/v)、30%至80%的乙醇(v/v)可以用于提取。提取溶剂的量可以优选为桃花或荷叶的干重的2至20倍。
根据本发明的一个实施方式,可以通过细切桃花或荷叶的各自干燥产物,将各个产物放入提取容器中,加入水或C1或C2低级醇,或它们的混合物,优选水,50%甲醇(v/v)、30%乙醇(v/v)或70%乙醇(v/v),并在预定温度下进行提取以制备单一提取物,然后将单一提取物以适当的比例混合,来制备桃花和荷叶的组合提取物。
然而,该方法仅是示例,制备桃花和荷叶的组合提取物的方法不限于此,并且本发明的桃花和荷叶的组合提取物包括桃花和荷叶的所有组合提取物,其根据本领域或相关领域中已知的方法制备。在本发明的制备方法中,当提取溶剂为水、50%甲醇(v/v)、30%乙醇(v/v)或70%乙醇(v/v)时,提取优选分别在100℃、80℃、85℃或80℃下进行。随后,可以将液体提取物进一步进行过滤,在减压下浓缩、干燥和粉碎。
在本发明中,桃花和荷叶的50%甲醇提取物是指约50%甲醇提取物,并且可以包括45%-55%的甲醇提取物。桃花和荷叶的30%乙醇提取物是指约30%的乙醇提取物,并可包括25%-35%的乙醇提取物。桃花和荷叶的70%乙醇提取物是指约70%乙醇提取物,并可包括65%-75%乙醇提取物。
如本文所用,术语“级分(fraction)”是指实施用于从包括各种组分的混合物中分离出特定组分或特定的组的分级而获得的产物。
在本发明中,对获得级分的分级方法没有特别限制,并且可以根据本领域通常使用的方法进行。分级方法的非限制性实例可包括在通过提取天然产物而获得提取物之后,通过用预定溶剂处理而从提取物中获得级分的方法。
在本发明中,用于获得级分的分级溶剂的种类没有特别限制,可以使用本领域中已知的任何溶剂。分级溶剂的非限制性实例可包括极性溶剂,例如水、醇等;和非极性溶剂,例如己烷、乙酸乙酯、氯仿、二氯甲烷等。这些溶剂可以单独使用,也可以将两种或以上组合使用。在分级溶剂中,当使用醇时,可以优选使用C1-C4醇。
本发明人首先发现桃花和荷叶的组合提取物对包括肥胖、糖尿病、高脂血症、血脂异常和非酒精性脂肪肝的代谢性疾病具有显著的治疗作用。特别地,根据本发明的实施方式,证实与桃花或荷叶的单一提取物相比,桃花和荷叶的组合提取物对高脂饮食喂养的小鼠具有优异的减轻体重和抑制脂肪的作用(图1和2),并且在如肥胖、糖尿病、高脂血症、非酒精性脂肪肝、血脂异常等代谢性疾病中观察到对血液因子具有优异的抑制作用(图3)。
如本文所用,术语“代谢性疾病”统指由糖、脂质、蛋白质、维生素、矿物质等的代谢异常引起的疾病。其具体实例可以包括由血糖代谢异常引起的肥胖和糖尿病、高脂血症、血脂异常以及由脂质代谢异常引起的非酒精性脂肪肝疾病等。
本发明中要预防或治疗的疾病包括所有肥胖或代谢性疾病,但是可以更优选地选自下组:血糖代谢异常引起的肥胖和糖尿病、和高脂血症、血脂异常和非酒精性脂肪肝疾病。
如本文所用,术语“肥胖”通常是指体重增加的状况,即体内过量脂肪堆积的状况,并且在病理学上被定义为体质指数(体重(kg)除以身高(m)的平方,在韩国为25或更多,而根据世界卫生组织(WHO)则为30或更多)。在大多数情况下,肥胖是指体重超过正常体重。然而,即使不超重,当身体成分中的脂肪比例高时,也被诊断为肥胖。肥胖是一种在成年人和儿童中都发生的疾病。已知在具有肥胖症状的个体中,从血浆进入脂肪细胞的脂肪酸和葡萄糖通常被酯化以甘油三酸酯的形式积累。
如本文所用,术语“糖尿病”是由缺乏胰岛素分泌或功能异常引起的疾病,其特征为升高的血糖水平(高血糖)和尿葡萄糖排泄的症状,从而导致视网膜病变、肾功能障碍、神经病、心血管疾病等。
如本文所用,术语“高脂血症”是指这样的疾病,其中血液中过量存在的脂肪成分积聚在血管壁上引起炎症,从而导致心血管疾病,并且已知高脂血症本身不表现出任何特殊症状,但可能会出现由于并发症引起的症状。例如,已知血液中甘油三酸酯升高可能导致胰腺炎、跟腱中的黄瘤或眼睑中的黄斑。
如本文所用,术语“血脂异常”是指血液中总胆固醇、LDL胆固醇或甘油三酸酯水平升高或HDL胆固醇水平降低的状况,并且已知会增加心血管疾病,例如心脏病发作、中风等的风险。已知血脂异常可能是由吸烟、饮酒等引起的,也可能是由遗传因素引起的。在诸如肥胖、糖尿病、高血压等疾病的情况下,血脂异常的风险增加是已知的。
如本文所用,术语“非酒精性脂肪肝疾病”是由脂肪肝疾病中除酒精以外的因素引起的脂肪肝疾病,是指脂肪酸以甘油三酸酯的形式在超过5%的肝实质细胞中积累。非酒精性脂肪肝疾病在病理上分为简单脂肪变性和有炎症的脂肪性肝炎。已知,如果长时间不治疗,非酒精性脂肪肝疾病可能会发展为严重的肝脏疾病,例如肝炎、肝纤维化、肝硬化等。
与桃花或荷叶的单一提取物相比,本发明的组合提取物表现出非常优异的脂肪抑制作用(图1和2),并且还表现出对与代谢性疾病如肥胖、糖尿病、高脂血症、非酒精性脂肪肝疾病、血脂异常等相关的血液因子的抑制作用(图3)。因此,本发明的桃花和荷叶的组合提取物可有效地用于预防或治疗肥胖或代谢性疾病。
包含本发明的组合提取物或其级分的药物组合物可以进一步包含通常用于制备药物组合物的合适的载体、赋形剂或稀释剂。在这方面,组合物中所含的组合提取物或级分的量没有特别限制,但是相对于组合物的总重量,优选以10重量%至70重量%的量包含组合提取物或级分,但不限于此。
此外,包含本发明的组合提取物或其级分的组合物可以按照常规方法配制成口服制剂,例如粉剂、颗粒剂、片剂、胶囊剂、混悬剂、乳剂、糖浆、气雾剂等,外用溶液、栓剂和无菌注射液后使用。可以包含在本发明的组合物中的载体、赋形剂和稀释剂可以包括乳糖、右旋糖、蔗糖、山梨糖醇、甘露醇、木糖醇、赤藓糖醇、麦芽糖醇、淀粉、阿拉伯胶、藻酸盐、明胶、磷酸钙、硅酸钙、纤维素、甲基纤维素、微晶纤维素、聚乙烯吡咯烷酮、水、甲基羟基苯甲酸酯、丙基羟基苯甲酸酯、滑石粉、硬脂酸镁和矿物油。对于制剂,可以使用常用的稀释剂或赋形剂(例如填充剂、增量剂、粘合剂、润湿剂、崩解剂、表面活性剂等)配制组合物。用于口服给药的固体制剂可以包括片剂、丸剂、散剂、颗粒剂、胶囊剂等,且这些固体制剂是通过将组合提取物或其级分与至少一种赋形剂例如淀粉、碳酸钙、蔗糖、乳糖、明胶等混合而制成的。此外,除了简单的赋形剂以外,可以使用润滑剂例如硬脂酸镁、滑石粉等。用于口服给药的液体制剂可以包括混悬剂、内服液体、乳剂、糖浆等,并且除了常用的简单稀释剂(如水、液体石蜡等)以外,还可以使用各种不同的赋形剂,例如润湿剂、甜味剂、矫味剂、防腐剂等。用于肠胃外给药的制剂可包括无菌水溶液、非水溶剂、悬浮液、乳剂、冻干制剂和栓剂。非水溶剂和悬浮液的例子可以包括丙二醇、聚乙二醇、植物油例如橄榄油,可注射的酯例如油酸乙酯等。栓剂基质的例子可以包括Witepsol、聚乙二醇、吐温61、可可脂、三月桂酸甘油酯黄油(laurin butter)、甘油明胶等。
本发明的组合提取物的优选给药剂量可以根据患者的状况和体重、疾病的严重程度,药物的形式以及给药途径和持续时间而变化,并且可以由本领域技术人员适当地选择。给药可以每天一次或等分剂量进行。
本发明的药物组合物可以通过各种途径给予哺乳动物,例如大鼠、小鼠、家畜、人等。可以考虑任何给药方式,例如口服、直肠、静脉内、肌肉内、皮下注射等。
预防或改善肥胖或代谢性疾病的食品组合物
作为实现本发明目的的另一方面,本发明提供了用于预防或改善肥胖或代谢性疾病的食品组合物,该食品组合物包括桃花和荷叶的组合提取物或其级分作为有效成分。
由于本发明的桃花和荷叶的组合提取物或其级分源自天然产物,并且其安全性已经证明,因此它也可用作食品组合物。
包含本发明的桃花和荷叶的组合提取物或其级分作为有效成分的食品组合物具有优异的减肥功效,并且具有改善肥胖或代谢性疾病的优异功效。
相对于组合物的总重量,优选以10重量%至70重量%的量包含本发明的桃花和荷叶的组合提取物或其级分,但不限于此。
本发明的食品组合物可以包括食品组合物中常用的附加成分,以改善气味、味道、视觉等。例如,该组合物可以包含维生素A、C、D、E、B1、B2、B6、B12、烟酸、生物素、叶酸、泛酸等。此外,所述组合物还可以包括矿物质,例如锌(Zn)、铁(Fe)、钙(Ca)、铬(Cr)、镁(Mg)、锰(Mn)、铜(Cu)等。此外,该组合物还可以包含氨基酸,例如赖氨酸、色氨酸、半胱氨酸、缬氨酸等。此外,该组合物还可以包含食品添加剂,例如防腐剂(山梨酸钾、苯甲酸钠、水杨酸、脱氢乙酸钠等)、消毒剂(漂白粉、高级漂白粉、次氯酸钠等)、抗氧化剂(丁基羟基茴香醚(BHA)、丁基羟基甲苯(BHT)等)、着色剂(焦油色等)、显色剂(亚硝酸钠等)、漂白剂(亚硫酸钠)、调味料(味精(MSG)等)、甜味剂(对乙氧基苯脲、环己基氨基磺酸盐(cyclemate)、糖精、钠等)、调味料(香草醛、内酯等)、溶胀剂(明矾、D-酒石酸氢钾等)、强化剂、乳化剂、增稠剂(胶浆)、成膜剂、胶基剂、消泡剂、溶剂、改良剂等。可以根据食品类型选择适当的添加量并使用。
在本发明的一个实施方式中,食品组合物可以是保健功能食品(healthfunctional food)或保健补充食品(health supplement food)。
如本文所用,术语“保健食品”是指与普通食品相比具有有效维持或促进健康的作用的食品,“保健补充食品”是指用于保健补充的食品。在某些情况下,术语“功能食品”,“保健食品”和“保健补充食品”可以互换使用。食品可以制成各种形式,例如片剂、胶囊剂、散剂、颗粒剂、液体剂、丸剂等,以获得有用的效果。
如本文所用,术语“功能食品”是与特殊保健用途的食品(FoSHU)相同的术语,并且是指具有高药用和医学效果的食品,其经过加工可有效发挥人体调节功能,并且提供营养。
作为本发明的保健功能食品的具体实例,桃花和荷叶的组合提取物或其级分可以用于提供加工食品,这些加工食品经修饰从而具有改善的储存性,同时保持农产品、畜产品,或水产品的性质。包括桃花和荷叶的组合提取物或其级分的保健功能食品可以是但不特别限于,优选以以下形式制备的那些:人造黄油、脂肪连续或水连续或双连续涂抹酱、少脂涂抹酱、糖果产品例如巧克力或巧克力涂层或巧克力馅料或烘焙食品馅料、冰淇淋、冰淇淋涂层、冰淇淋夹杂物、调味品、蛋黄酱、奶酪、奶油替代品、干汤、饮料、谷物棒、调味料、小吃店、乳制品、临床营养产品、婴儿配方等。
桃花和荷叶的组合提取物及其级分的用途及使用桃花和荷叶的组合提取物及其
级分的治疗方法
本发明提供了桃花和荷叶的组合提取物或其级分在制备用于肥胖或代谢性疾病的治疗剂中的用途。
此外,本发明提供了预防、改善或治疗肥胖或代谢性疾病的方法,该方法包括以下步骤:将治疗有效量的桃花和荷叶的组合提取物或其级分施用于需要预防或治疗肥胖或代谢性疾病的受试者。在本发明中,受试者可以是哺乳动物,特别是人。
【有益效果】
本发明的桃花和荷叶的组合提取物或其级分对肥胖或代谢性疾病具有优异的功效,并且没有副作用,因为其源自天然产物,因此,它可能是被广泛应用于预防、改善或治疗肥胖或代谢性疾病。
【附图说明】
图1是显示高脂饮食喂养的小鼠模型中总体重和体重增加的比较的图,各小鼠模型饲以桃花的单一提取物(用桃花表示)、荷叶的单一提取物(用荷叶表示)、或本发明的组合提取物(由组合1或组合2表示);
图2是显示高脂饮食小鼠模型中异常脂肪重量、肾周脂肪重量、肠系膜脂肪重量和总脂肪重量的比较的图,各小鼠模型饲以桃花的单一提取物(用桃花表示)、荷叶的单一提取物(以荷叶表示)或本发明的组合提取物(以组合1或组合2表示);和
图3是显示高脂饮食喂养的小鼠模型中肝酶水平(ALT和AST)、葡萄糖水平和甘油三酸酯(TG)水平的比较的图,各小鼠模型饲以桃花的单一提取物(用桃花表示)、荷叶的单一提取物(由荷叶表示)或本发明的组合提取物(由组合1或组合2表示)。
【发明模式】
在下文中,将参考制备实施例和实施例更详细地描述本发明。然而,这些制备实施例和实施例仅用于说明目的,并且本发明的范围不旨在由这些制备实施例和实施例限制。
<制备实施例>单一提取物或组合提取物的制备
制备实施例1:桃花的单一提取物的制备
将桃花的干燥产物细切,然后放入提取容器中。向其中添加水,然后在100℃下3小时回流提取两次。使用滤纸过滤液体提取物,然后使用旋转真空蒸发器(EYELA,日本)在减压下浓缩,随后使用冷冻干燥机(OPR-FDY-8612,OPERON,韩国)冷冻干燥从而制备桃花的单一提取物。
制备实施例2:荷叶的单一提取物的制备
将荷叶的干燥产物细切,然后以与制备实施例1相同的方式提取并冷冻干燥,从而制备荷叶的单一提取物。
制备实施例3:本发明的桃花与荷叶组合提取物的制备
将制备实施例1中制备的桃花的单一提取物和制备实施例2中制备的荷叶的单一提取物按下表中的重量比混合,从而制备本发明的组合提取物。
[表1]
制备实施例 | 桃花 | 荷叶 |
3-1 | 1 | 1 |
3-2 | 2 | 1 |
制备实施例4:本发明的桃花与荷叶组合提取物的制备
将桃花和荷叶的各干燥产物细切,然后按照下表2中的重量比混合,以与制备实施例1相同的方式提取并冷冻干燥,从而制备本发明的组合提取物。
[表2]
制备实施例 | 桃花 | 荷叶 |
4-1 | 1 | 1.35 |
4-2 | 1 | 0.65 |
实施例1:在高脂饮食小鼠模型中检查体内脂肪减少效果
为了检查本发明的桃花和荷叶组合提取物的减肥效果,购买了21天大(3周大)的雄性小鼠C57BL/6,并使其自由获取水和进食(饲料)1周。当实验动物为4周龄时,对实验动物的体重进行测量和排列,以使每个笼子的平均体重偏差均匀地在0.1g之内,并通过如下表3所示改变饮食条件共分为6组(每组n=8)。之后,将高脂肪饲料(60%千卡脂肪)与对应于下表3各组的提取物混合饲喂,每3-4天一次,共持续8周。
[表3]
结果,与饲喂桃花的单一提取物的小鼠模型相比,饲喂本发明的桃花和荷叶的组合提取物的小鼠模型表现出优异的减肥效果。特别地,即使荷叶的单一提取物没有减肥作用,但是与桃花的单一提取物相比,其中桃花量减少到桃花的单一提取物的1/2的桃花和荷叶的组合提取物也表现出更好的减肥效果(图1)。
同时,为了检查减肥效果是否是脂肪抑制效果,测量并记录实验动物每个身体部位的脂肪质量。详细地,在完成实验之后,去除并称重实验动物的腹部脂肪、肾周脂肪和肠系膜脂肪。
结果,证实了与饲喂桃花的单一提取物或荷叶的单一提取物的小鼠模型相比,饲喂本发明的桃花和荷叶的组合提取物的小鼠模型对所有身体区域的脂肪量均表现出优异的抑制作用(图2)。
这些结果表明,与桃花的单一提取物或荷叶的单一提取物相比,本发明的桃花和荷叶的组合提取物表现出显著优异的脂肪抑制效果,因此可有效地用于预防或治疗如肥胖等代谢性疾病。
实施例2:检查高脂饮食喂养的小鼠模型中肥胖或代谢性疾病标志物在血液中的
减少作用
为了进一步检查本发明的桃花和荷叶的组合提取物在预防或治疗代谢性疾病中是有效的,在去除实施例1中所用小鼠的脂肪组织之前收集的血液中分离的血浆中测量了肝丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)水平、血糖水平和甘油三酸酯(TG)。
结果,与饲喂桃花的单一提取物或荷叶的单一提取物的小鼠模型相比,当高脂饮食的小鼠模型饲喂本发明的桃花和荷叶的组合提取物时,该组合提取物对在代谢性疾病(例如肥胖、糖尿病、高脂血症、血脂异常、非酒精性脂肪肝等)中长期过高的所有血液ALT和AST水平、血糖水平和甘油三酸酯(TG)的水平的抑制作用显著增加(图3)。
这些结果表明,与桃花的单一提取物或荷叶的单一提取物相比,本发明的桃花和荷叶的组合提取物对代谢性疾病的治疗效果显著提高,因此其可以有效地应用于预防或治疗如肥胖、糖尿病、高脂血症、血脂异常、非酒精性脂肪肝等的代谢性疾病。
因为本领域技术人员可以充分认识和推断内容,因此将省略其详细描述。除了本说明书中描述的具体示例之外,在不改变本发明的技术精神或基本配置的情况下,可以进行各种不同的修改。因此,可以以与本说明书中具体描述和例举的那些不同的方式来实现本发明,这是本发明技术领域的任何技术人员所理解的。
Claims (10)
1.一种用于预防或治疗肥胖或代谢性疾病的药物组合物,所述药物组合物包含桃花和荷叶的组合提取物或其级分作为活性成分。
2.根据权利要求1所述的药物组合物,其特征在于,所述组合提取物是桃花提取物和荷叶提取物的混合物,或者是通过提取桃花和荷叶的混合物而获得的提取物。
3.根据权利要求2所述的药物组合物,其特征在于,所述组合提取物是用水、C1-C4醇或其混合物提取的。
4.根据权利要求1所述的药物组合物,其特征在于,所述药物组合物用于预防或治疗肥胖。
5.根据权利要求1所述的药物组合物,其特征在于,所述药物组合物用于预防或治疗代谢性疾病,且所述代谢性疾病选自下组:糖尿病、高脂血症、血脂异常和非酒精性脂肪肝。
6.根据权利要求1所述的药物组合物,其特征在于,所述组合提取物或其级分具有减肥作用。
7.一种用于预防或改善肥胖或代谢性疾病的食品组合物,该食品组合物包含桃花和荷叶的组合提取物或其级分作为活性成分。
8.根据权利要求7所述的食品组合物,其特征在于,所述组合物是保健功能食品或保健补充食品。
9.一种预防或治疗肥胖或代谢性疾病的方法,该方法包括以下步骤:向需要预防或治疗肥胖或代谢性疾病的受试者施用治疗有效量的桃花和荷叶的组合提取物或其级分。
10.桃花和荷叶的组合提取物或其级分在制备用于肥胖或代谢性疾病的预防剂或治疗剂中的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0143819 | 2017-10-31 | ||
KR1020170143819A KR101886299B1 (ko) | 2017-10-31 | 2017-10-31 | 도화 및 하엽 복합 추출물을 포함하는 비만 및 대사성 질환의 예방, 개선 또는 치료용 조성물 |
PCT/KR2018/005429 WO2019088381A1 (ko) | 2017-10-31 | 2018-05-11 | 도화 및 하엽 복합 추출물을 포함하는 비만 및 대사성 질환의 예방, 개선 또는 치료용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111757749A true CN111757749A (zh) | 2020-10-09 |
Family
ID=63443895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880084519.9A Pending CN111757749A (zh) | 2017-10-31 | 2018-05-11 | 用于预防、改善或治疗肥胖和代谢性疾病的包含桃花和荷叶的组合提取物的组合物 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3705129A4 (zh) |
KR (1) | KR101886299B1 (zh) |
CN (1) | CN111757749A (zh) |
WO (1) | WO2019088381A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116407580A (zh) * | 2023-03-28 | 2023-07-11 | 五邑大学 | 素馨花提取物在调节肠道菌群及改善代谢综合征中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101816719A (zh) * | 2009-12-31 | 2010-09-01 | 王宝民 | 桃花或桃叶总黄酮及它们在制备降血糖血脂、预防和/或治疗糖尿病及并发症药物或保健品中的用途 |
CN106620516A (zh) * | 2016-12-07 | 2017-05-10 | 庞秀军 | 一种用于养生减肥的中药组合物及其制剂和制法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070041927A (ko) | 2005-10-17 | 2007-04-20 | 안봉전 | 항산화, 항암, 미백 활성을 나타내는 도화 추출물을함유하는 조성물 |
KR100854442B1 (ko) | 2006-07-05 | 2008-08-26 | 박영준 | 하엽 추출물 또는 생약복합제 추출물을 함유하는 고지혈증 및 동맥경화증의 예방 및 치료용 조성물 |
KR100804104B1 (ko) | 2006-07-06 | 2008-02-18 | 주식회사 워터비스 | 복숭아꽃 추출물과 해양 심층수 주요 미네랄로 조성된 음료및 건강 식품용 조성물 |
KR20090094614A (ko) * | 2008-03-03 | 2009-09-08 | 목포대학교산학협력단 | 연잎에서 추출한 추출물을 함유한 당뇨성 예방 및 치료효능을 갖는 약학 조성물 및 건강식품 |
JP2010270096A (ja) | 2009-05-19 | 2010-12-02 | Miyuki Shirosaki | グルコース吸収抑制剤 |
KR101176435B1 (ko) * | 2010-02-22 | 2012-08-30 | 인하대학교 산학협력단 | 연잎 추출물 및 타우린을 함유하는 대사성 질환 예방 및 치료용 조성물 |
KR20140015662A (ko) | 2012-06-29 | 2014-02-07 | 목포대학교산학협력단 | 하엽 및 비파엽 추출물을 유효성분으로 함유하는 비만증의 치료 및 예방을 위한 조성물 |
CN104643036A (zh) * | 2013-11-18 | 2015-05-27 | 吴凡 | 减肥功能食品 |
CN104146211B (zh) * | 2014-08-28 | 2016-03-23 | 安徽燕之坊食品有限公司 | 一种解暑粥及其制备方法 |
CN105360507A (zh) * | 2015-11-23 | 2016-03-02 | 刘韶娜 | 一种花草减肥茶 |
-
2017
- 2017-10-31 KR KR1020170143819A patent/KR101886299B1/ko active IP Right Grant
-
2018
- 2018-05-11 CN CN201880084519.9A patent/CN111757749A/zh active Pending
- 2018-05-11 EP EP18872129.4A patent/EP3705129A4/en active Pending
- 2018-05-11 WO PCT/KR2018/005429 patent/WO2019088381A1/ko unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101816719A (zh) * | 2009-12-31 | 2010-09-01 | 王宝民 | 桃花或桃叶总黄酮及它们在制备降血糖血脂、预防和/或治疗糖尿病及并发症药物或保健品中的用途 |
CN106620516A (zh) * | 2016-12-07 | 2017-05-10 | 庞秀军 | 一种用于养生减肥的中药组合物及其制剂和制法 |
Non-Patent Citations (3)
Title |
---|
CARRSEYSCK: "荷叶桃花茶(超级减肥茶)", 《下厨房(HTTPS://WWW.XIACHUFANG.COM/RECIPE/100551573/)》 * |
关章顺等: "荷叶水提物对人体高脂血症的降脂效果研究", 《郴州医学高等专科学校学报》 * |
范婷婷等: "荷叶总生物碱降脂减肥作用的体内外试验", 《浙江大学学报(农业与生命科学版)》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019088381A1 (ko) | 2019-05-09 |
EP3705129A1 (en) | 2020-09-09 |
EP3705129A4 (en) | 2021-06-16 |
KR101886299B1 (ko) | 2018-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102110040B1 (ko) | 토종보리수 추출물을 포함하는 비만 또는 대사성 질환의 예방 및 치료용 조성물 | |
KR20120002131A (ko) | 울금 추출물을 함유하는 비만 치료 또는 예방용 조성물 | |
KR101691205B1 (ko) | 한약재의 추출물을 유효성분으로 포함하는 지방간 질환의 예방 또는 치료용 조성물 | |
WO2013133649A1 (ko) | 율초 추출물의 대사성 질환 또는 지방간의 예방 또는 치료용도 | |
KR101621447B1 (ko) | 삼백초, 강황 및 원지의 복합추출물을 포함하는 비만의 예방 또는 치료용 약학 조성물 | |
WO2009101698A1 (ja) | 脂肪蓄積を抑制するための組成物及び方法 | |
KR101461098B1 (ko) | 구기자 추출물, 어성초 추출물 및 삼백초 추출물을 유효성분으로 포함하는 비만관련질환의 예방 또는 치료용 약학적 조성물, 식품 조성물 및 육류 조리용 기능성 소스 | |
KR101402936B1 (ko) | 죽엽 추출물 및 황금 추출물을 포함하는 비만 억제 활성을 나타내는 조성물 및 이의 용도 | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
KR102152947B1 (ko) | 도화 및 하엽 복합 추출물을 포함하는 비알코올성 지방간의 예방, 개선 또는 치료용 조성물 | |
CN111757749A (zh) | 用于预防、改善或治疗肥胖和代谢性疾病的包含桃花和荷叶的组合提取物的组合物 | |
KR102436692B1 (ko) | 견사단백질을 갖는 익힌 누에가공물을 포함하는 비만의 예방 또는 치료용 조성물 | |
JP5177676B2 (ja) | 脂肪吸収抑制剤及びそれを用いた飲食品 | |
KR102288366B1 (ko) | 한속단 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물 | |
KR102152959B1 (ko) | 도화 및 마름 복합 추출물을 포함하는 비알코올성 지방간의 예방, 개선 또는 치료용 조성물 | |
KR20090099974A (ko) | 상엽 추출물을 유효성분으로 함유하는 고지혈증 또는비만의 예방 및 치료용 조성물 | |
KR101851639B1 (ko) | 모과 추출물 또는 이의 분획물을 유효성분으로 함유하는 항비만용 조성물 | |
KR101886314B1 (ko) | 도화 및 마름 복합 추출물을 포함하는 비만 및 대사성 질환의 예방, 개선 또는 치료용 조성물 | |
KR101521341B1 (ko) | 북두근, 북두근 추출물, 북두근 오니 또는 북두근 맥아 효소액 추출물을 유효성분으로 함유하는 식욕부진 예방 또는 치료용 조성물 | |
JPH07274832A (ja) | 飲食物、飲食物素材、およびそれらの製造法 | |
KR101344564B1 (ko) | 마라소스의 주성분인 고추 및 화초 추출물을 유효성분으로 함유하는 비만 또는 고지혈증 예방 및 치료용 조성물 | |
KR20190049409A (ko) | 도화 및 하엽 복합 추출물을 포함하는 비만 및 대사성 질환의 예방, 개선 또는 치료용 조성물 | |
KR20160059152A (ko) | 엉겅퀴 잎 추출물을 유효성분으로 함유하는 항비만 조성물 | |
KR20190049410A (ko) | 도화 및 마름 복합 추출물을 포함하는 비만 및 대사성 질환의 예방, 개선 또는 치료용 조성물 | |
KR20150072659A (ko) | 청미래 추출물을 포함하는 간 보호용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201009 |
|
RJ01 | Rejection of invention patent application after publication |